Modified release tizanidine in the treatment of spasticity.
A 6-week study of a modified release formulation of tizanidine designed for once daily administration was performed in 27 patients with spasticity due to cerebral lesions. The dosage of tizanidine used ranged from 6 to 18 mg/day. At the start of the study all patients had at least moderate spasticity and 20 (74%) patients had severe or very severe spasticity. All had a decrease in muscle strength. After 1 week of treatment 22 (81%) patients showed improvement in overall spastic state and, after 6 weeks, all 27 patients had improved. At the end of treatment 25 (93%) patients showed an improvement in overall disability. The drug was well tolerated. Side-effects were reported in only four patients, and these were minor and mostly mild. Tizanidine had no clinically important effects on blood pressure, heart rate, body weight or laboratory values. Overall, once daily treatment with modified release tizanidine is well tolerated and gives good clinical efficacy in patients with spasticity.
Chantraine
A
A
Department of Rehabilitation Medicine, University Hospital, Geneva, Switzerland.
Van Ouwenaller
C
C
D000328:Adult; D001925:Brain Damage, Chronic / Q000150:complications*; D003000:Clonidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004304:Dosage Forms; D005260:Female; D006801:Humans; D008297:Male; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*
D004304:Dosage Forms; D009125:Muscle Relaxants, Central; C023754:tizanidine; D003000:Clonidine